13F Filings History of COURAGE CAPITAL MANAGEMENT LLC
- Latest 13F filing
- Q2 2026 - 11 Aug 2026
- Latest reported 13F value
- $67,312,000
- Largest 13F holdings
-
BKLN CXW PHYS AAAU FBTC SPY META GOOG TSLA PNFP IAU UNH
+4 more
AMZN JNJ HCA TYL - Form 13F summary
-
- COURAGE CAPITAL MANAGEMENT LLC Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- COURAGE CAPITAL MANAGEMENT LLC reported 16 equity holdings with a total reported market value of $67,312,000 for Q2 2026. Top reported holdings included BKLN, CXW, PHYS, AAAU, and FBTC.
- Manager signature
- Richard C. Patton - Chief Manager
- Manager location
- Nashville, TN
13F snapshot
Latest parsed holdings, value, and filing-period context.
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow COURAGE CAPITAL MANAGEMENT LLC with Pro and return when a new 13F portfolio filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
Holdings Value
Form 13F evidence
Quarterly portfolio filings
SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.
Latest quarter
Q2 2026
Latest value
$67,312,000
Quarter delta
-$3,312,000
Accepted
11 Aug 2026, 15:48
Rows shown
1-25 of 51
| Quarter | Holdings | SEC-reported value | Bought | Sold | Net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | 16 | $67,312,000 | +$760,000 | -$7,820,368 | -$7,060,368 | BKLN, CXW, PHYS, AAAU, FBTC | 13F-HR | 11 Aug 2026, 15:48 |
| Q1 2026 | 14 | $70,624,000 | +$1,908,223 | $0 | +$1,908,223 | BKLN, FBTC, PHYS, CXW, AAAU | 13F-HR | 14 May 2026, 16:30 |
| Q4 2025 | 13 | $72,356,000 | +$381,149 | -$1,489,144 | -$1,107,995 | BKLN, FBTC, CXW, PHYS, AAAU | 13F-HR | 17 Feb 2026, 16:02 |
| Q3 2025 | 14 | $75,685,000 | +$3,391,402 | $0 | +$3,391,402 | FBTC, BKLN, CXW, PHYS, AAAU | 13F-HR | 12 Nov 2025, 10:18 |
| Q2 2025 | 13 | $67,804,000 | +$16,135,389 | -$1,251,000 | +$14,884,389 | FBTC, BKLN, CXW, PHYS, AAAU | 13F-HR | 15 Aug 2025, 09:13 |
| Q1 2025 | 12 | $48,974,000 | +$1,605,055 | -$1,758,034 | -$152,979 | BKLN, CXW, PHYS, FBTC, AAAU | 13F-HR | 14 May 2025, 11:38 |
| Q4 2024 | 12 | $48,458,000 | +$3,725,864 | -$363,000 | +$3,362,864 | BKLN, CXW, FBTC, PHYS, AAAU | 13F-HR | 14 Feb 2025, 10:42 |
| Q3 2024 | 11 | $40,363,000 | +$4,201,852 | -$5,513,000 | -$1,311,148 | BKLN, PHYS, CXW, AAAU, META | 13F-HR | 14 Nov 2024, 17:51 |
| Q2 2024 | 12 | $39,607,000 | +$5,362,168 | -$252,133 | +$5,110,035 | BKLN, Coherus Biosciences Inc, CXW, PHYS, AAAU | 13F-HR | 14 Aug 2024, 18:08 |
| Q1 2024 | 12 | $34,525,000 | +$13,253,000 | -$5,967,625 | +$7,285,375 | CXW, BKLN, Coherus Biosciences Inc, PHYS, AAAU | 13F-HR | 10 May 2024, 15:02 |
| Q4 2023 | 11 | $24,775,000 | +$354,000 | -$6,142,600 | -$5,788,600 | Coherus Biosciences Inc, PHYS, Evolent Health Inc, AAAU, META | 13F-HR | 12 Feb 2024, 10:48 |
| Q3 2023 | 12 | $29,484,000 | $0 | -$6,182,250 | -$6,182,250 | Coherus Biosciences Inc, PHYS, Coherus Biosciences Inc, AAAU, META | 13F-HR | 08 Nov 2023, 16:48 |
| Q2 2023 | 17 | $36,431,000 | +$3,111,838 | -$7,031,195 | -$3,919,357 | Coherus Biosciences Inc, PHYS, General Dynamics Corp, AAAU, META | 13F-HR | 14 Aug 2023, 16:50 |
| Q1 2023 | 17 | $41,711,000 | +$5,430,084 | -$2,558,000 | +$2,872,084 | Coherus Biosciences Inc, General Dynamics Corp, AAAU, PHYS, BRY | 13F-HR | 15 May 2023, 10:49 |
| Q4 2022 | 18 | $35,596,000 | +$1,203,000 | -$9,435,155 | -$8,232,155 | Coherus Biosciences Inc, Evolent Health Inc, AAAU, PHYS, MSFT | 13F-HR | 13 Feb 2023, 18:42 |
| Q3 2022 | 18 | $46,172,000 | +$3,694,500 | -$20,147,354 | -$16,452,854 | Coherus Biosciences Inc, Evolent Health Inc, AAAU, CHRD, PDCE | 13F-HR | 14 Nov 2022, 14:14 |
| Q2 2022 | 22 | $60,837,000 | +$23,087,516 | -$61,247,920 | -$38,160,404 | Coherus Biosciences Inc, Evolent Health Inc, CHK, WLL, CEIX | 13F-HR | 12 Aug 2022, 14:42 |
| Q1 2022 | 34 | $104,787,000 | +$21,020,460 | -$61,013,749 | -$39,993,289 | Coherus Biosciences Inc, Evolent Health Inc, CHK, MSFT, GOOG | 13F-HR | 16 May 2022, 15:10 |
| Q4 2021 | 38 | $149,344,000 | +$10,199,274 | -$40,560,636 | -$30,361,362 | Coherus Biosciences Inc, Evolent Health Inc, EXC, EVH, Evolent Health Inc | 13F-HR | 14 Feb 2022, 15:19 |
| Q3 2021 | 40 | $185,262,000 | +$45,939,979 | -$27,819,824 | +$18,120,155 | Coherus Biosciences Inc, Evolent Health Inc, Evolent Health Inc, BCEI, EVH | 13F-HR | 15 Nov 2021, 12:27 |
| Q2 2021 | 38 | $166,575,000 | +$82,061,229 | -$69,719,862 | +$12,341,367 | Coherus Biosciences Inc, Evolent Health Inc, CHRD, EVH, VEI | 13F-HR | 13 Aug 2021, 11:43 |
| Q1 2021 | 40 | $136,856,000 | +$53,639,474 | -$10,093,194 | +$43,546,280 | CHRD, CHK, EVOLENT HEALTH INC, EVOLENT HEALTH INC, VTRS | Restatement | 18 May 2021, 11:45 |
| Q4 2020 | 31 | $81,069,000 | +$42,864,778 | -$31,667,540 | +$11,197,238 | CHRD, Evolent Health Inc, VTRS, CCI, EVH | 13F-HR | 16 Feb 2021, 08:54 |
| Q3 2020 | 28 | $64,460,000 | +$22,958,041 | -$7,822,957 | +$15,135,084 | Evolent Health Inc, MYL, CCI, EVH, Centene Corp. | 13F-HR | 16 Nov 2020, 10:31 |
| Q2 2020 | 24 | $48,322,000 | +$22,159,200 | -$20,779,944 | +$1,379,256 | MYL, Evolent Health Inc, CCI, HCA, HNGR | 13F-HR | 14 Aug 2020, 09:51 |